SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
OSI Pharmaceuticals (OSIP) - formerly Oncogene
An SI Board Since December 1997
Posts SubjectMarks Bans Symbol
447 40 0 OSIP
Emcee:  James Reynolds Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
197OSI Pharmaceuticals Announces Restructuring to Focus R&D Efforts On Oncologynigel bates-10/24/2002
196OT Wouldn't do any good to go right back to the text. My paraphrase was thekeokalani'nui-10/17/2002
195OT Re: iressa on IMCL thread >> several comments on the lipid-loving quatuck-10/17/2002
194<<I like the ABGX business model, but you have taught me to watch the moleMiljenko Zuanic-10/17/2002
193Full quote, with emphasis: <i>This side-effect was <b>known to Astrkeokalani'nui-10/16/2002
192I suppose it could be an unconsidered - and inaccurate - comment from the spokesnigel bates-10/16/2002
191That phrase "throughout the drug's clinical development" is very ituck-10/16/2002
190<i>We do not know Iressa PIII tox profile for stage IIIb/IV NSCLC...</inigel bates-10/16/2002
189Miljenko, I like the ABGX business model, but you have taught me to watch the mtuck-10/16/2002
188Tuck, IF you do not believe in ABGX business model that @5 is too expensive. IFMiljenko Zuanic-10/16/2002
187>>Nonetheless, market is acting like this are FACTS (for ABGX and OSIP).&ltuck-10/16/2002
186Tuck, Similar questions I asked myself. We do not know Iressa PIII tox profile Miljenko Zuanic-10/16/2002
185>>I thought that diarrhea is main toxic issue and DLT. Wondering what perctuck-10/16/2002
184It sounds as very serious. JMH claims that I. P. is main reason for this death.Miljenko Zuanic-10/15/2002
183From> Briefing.com: >>7:26AM AstraZeneca: Iressa deaths reported in Jatuck-10/15/2002
182So far (and to my knowledge) this is first trial which will combine VEGFr-EGFr iMiljenko Zuanic-9/24/2002
18109/24 4:19P (DJ) +DJ OSI Pharma Up 28% After FDA Advisory Panel Comments Wow,Vector1-9/24/2002
180The rec from the briefing materials. Really a punt> 10.1 Recommendation TheVector1-9/24/2002
179Meanhwile, Iressa looking wobbly a day before its ODAC meeting. >>WASHINGtuck-9/23/2002
178MELVILLE, N.Y.--(BUSINESS WIRE)--Sept. 23, 2002--OSI Pharmaceuticals, Inc. (Nasdnigel bates-9/23/2002
177From SSB pt II: * Competitive Risk Several companies are developing EGFR inhibmopgcw-9/19/2002
176From SSB: OSI Pharmaceuticals (OSIP) OSIP: Initiation of Coverage mopgcw-9/19/2002
175>>MELVILLE, N.Y.--(BUSINESS WIRE)--Aug. 29, 2002--OSI Pharmaceuticals, Inctuck-8/29/2002
174Thanks Tuck. I have talked to a number of oncologists and MBs following the IRREVector1-8/28/2002
173At that time Tarceva was completing PIb fase and CI-1033 was at mid-preclinical Miljenko Zuanic-8/28/2002
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News